<SEC-DOCUMENT>0001193125-25-280784.txt : 20251114
<SEC-HEADER>0001193125-25-280784.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251113203917
ACCESSION NUMBER:		0001193125-25-280784
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251113
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251480632

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d895636d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as November 13, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#8217;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#8220;Yes&#8221; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d895636dex991.htm">Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 13, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d895636dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g895636g10b28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Translational Data and Significant Pathologic Response Rates from </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B><FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> Phase II Highlighted in Oral Presentation at CTOS 2025 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis
across multiple soft tissue sarcoma subtypes including rare and highly aggressive tumours with poor prognosis </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Early translational data show a strong immune system activation inline with efti&#8217;s mode of action with
statistically-significant increases in multiple cytokines and chemokines </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">High levels of key immune proteins in <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> including interferon-gamma <FONT
STYLE="white-space:nowrap">(IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>) correlate with pathologic responses indicating a significant destruction/alteration of tumour tissue following
treatment, which is generally associated with better outcomes for patients and potentially improved survival rates </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>SYDNEY,
AUSTRALIA &#8211; November</B><B></B><B>&nbsp;13, 2025 &#8211;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep&#8221; or &#8220;the Company&#8221;), a late-stage immunotherapy company targeting cancer and autoimmune diseases,
today announces positive data from the <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> trial that were detailed in an oral presentation by Pawe&#322; Sobczuk, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw,
Poland, at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting held in Boca Raton, Florida. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The investigator-initiated Phase II study
evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) significantly exceeded the study&#8217;s
prespecified level of pathologic response rates. In the evaluable patient population (N=38), the novel combination with efti reached a median 51.5% tumour hyalinization/fibrosis (p&lt;0.001), meeting the study&#8217;s primary endpoint.<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">These promising results were achieved in patients with ten different STS subtypes including rare
and/or highly aggressive tumours with poor prognosis such as myxofibrosarcoma (N=16), undifferentiated pleomorphic sarcoma (N=10) and malignant peripheral nerve sheath tumor (N=2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Early translational data from the initial twenty patients who underwent surgery in the trial show a strong immune system activation in line with
efti&#8217;s mode of action, with statistically significant increases in the expression of key cytokines and chemokines in peripheral blood &#8212; specifically CXCL9, CXCL10, <FONT STYLE="white-space:nowrap">IL-23,</FONT> and <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Immune
Response</B><B></B><B>&nbsp;Biomarkers </B><I>(fold change from week 1 through <FONT STYLE="white-space:nowrap">pre-surgery)</FONT></I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:SimHei; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:SimHei; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Arial; " ALIGN="center"><B>Serum Biomarker</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Arial; "><B><FONT STYLE="white-space:nowrap">Fold&nbsp;change&nbsp;(p-value)</FONT></B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:SimHei; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Arial" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">C-X-C</FONT></FONT> motif chemokine ligand 9
(CXCL9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Arial; ">2.5x&nbsp;(p&lt;0.01)</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:SimHei; font-size:10pt">
<TD VALIGN="top" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Arial" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">C-X-C</FONT></FONT> motif chemokine ligand 10
(CXCL10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Arial; ">1.8x&nbsp;(p&lt;0.0001)</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:SimHei; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Arial" ALIGN="center"><FONT STYLE="white-space:nowrap">Interleukin-23</FONT> <FONT
STYLE="white-space:nowrap">(IL-23)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Arial; ">2.2x&nbsp;(p&lt;0.05)</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:SimHei; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Arial" ALIGN="center">Interferon-gamma <FONT STYLE="white-space:nowrap">(IFN-</FONT><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Arial; ">2.5x&nbsp;(p&lt;0.05)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The increase on treatment of immune response biomarkers like <FONT STYLE="white-space:nowrap">IFN-gamma</FONT>
correlated with pathologic responses in this study, meaning patients with a biomarker increase during treatment also had a higher probability of a good clinical response at surgery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g895636g78t64.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The promising tumour hylanization/fibrosis rate achieved (over 3X greater than <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> radiotherapy based on historical data)<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> may hold significance in terms of future outcomes as it serves as
an early surrogate endpoint correlated with enhanced overall survival and recurrence-free survival in STS patients.<SUP STYLE="font-size:75%; vertical-align:top">2,3</SUP> Disease-free survival and overall survival data are immature at this stage
and will be presented in the future. Further correlative translational studies are also ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Pawe</B><B>&#322;</B><B>
Sobczuk, one of the trial&#8217;s principal investigators, stated</B>: &#8220;We are excited to share these strong results in resectable soft tissue sarcoma, a challenging indication with a high unmet medical need. This level of efficacy, observed
across ten different STS subtypes including rare, highly aggressive tumours with poor prognosis, further supports the hypothesis that efti&#8217;s distinctive activation of antigen-presenting cells&#8212;and consequent induction of both adaptive and
innate immunity&#8212;plays a key role in driving a coordinated immune response to fight cancer. This novel combination with neoadjuvant efti warrants further investigation in registrational settings.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">&#8220;Our team was delighted to have recently been awarded the distinguished Golden Scalpel Award (Z&#322;oty Skalpel)* for <FONT
STYLE="white-space:nowrap">EFTISARC-NEO.</FONT> This honour is reserved for projects that demonstrate exceptional innovation and impact in medical research and clinical practice,&#8221; added Dr.&nbsp;Sobczuk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Fr&eacute;d&eacute;ric Triebel, CSO of Immutep, said:</B> &#8220;We are pleased to see a confirmation of earlier promising
data on now 38 patients in this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancer. The prolonged increase in serum immune response biomarkers, observed two weeks after efti subcutaneous
injection, is indicative of a robust adaptive and innate immune response. This enhanced immune activity is crucial because it means the body&#8217;s own defences are being mobilised to target and destroy cancer cells more effectively, further
supporting the positive impact of the observed pathologic responses. The recent results suggest that efti may have potential applications beyond advanced or metastatic cancer, extending into earlier-stage disease.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">As neoadjuvant immunotherapy becomes more established in the treatment of early-stage cancers, the findings from
<FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> highlight the possibility for efti to be used in patients who have a lower tumor burden at diagnosis. This could expand the range of patients who might benefit from efti, potentially increasing
its role in the treatment landscape for cancers that are still localized and resectable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">STS is an orphan disease with high unmet medical need and
a poor prognosis for patients. The incidence of STS varies in different regions globally. In the United States, the number of new STS cases in 2025 is estimated to be ~13,520 with ~5,420 deaths, according to the American Cancer Society.<SUP
STYLE="font-size:75%; vertical-align:top">4</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">For more information on <FONT STYLE="white-space:nowrap">EFTISARC-NEO,</FONT> visit
clinicaltrials.gov (NCT06128863).<B> </B>The CTOS 2025 oral presentation slides can be found on the <U>Posters&nbsp;&amp; Publications page of Immutep&#8217;s website</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>*About the Golden Scalpel Award in Poland </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The Golden Scalpel
Award in Poland is recognized as a benchmark of excellence within the medical community. It is presented by independent experts to initiatives that set new standards in advancing healthcare. This year, EFTISARC NEO was the only oncology project to
receive this accolade, underscoring its leadership and breakthrough potential in cancer treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g895636g78t64.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>About Eftilagimod Alfa (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Efti is a novel immunotherapy that directly activates antigen-presenting cells or APCs (e.g. dendritic cells, monocytes) via the MHC Class&nbsp;II
pathway to fight cancer. As an MHC Class&nbsp;II agonist, its activation of APCs engages the adaptive and innate immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as
generating important <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> signals&nbsp;&amp; cytokines that further boost the immune system&#8217;s ability to combat cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in a
pivotal Phase III trial called <FONT STYLE="white-space:nowrap">TACTI-004</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-F91),</FONT> as well as head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable
safety profile enables various combinations like with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy, radiotherapy, and/or chemotherapy. Efti has received Fast Track designation in first
line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease<I>.</I> The Company is a pioneer in the
understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT><B> </B><FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT
STYLE="white-space:nowrap">LAG-3&#8217;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders.
For more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Arial; " ALIGN="justify"><I>ESMO Congress 2025 Proffered Paper presentation, <FONT STYLE="white-space:nowrap">&#8220;EFTISARC-NEO:</FONT> A
phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma&#8221;. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Arial; " ALIGN="justify"><I>Schaefer IM et al. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment
of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017 Jun <FONT STYLE="white-space:nowrap">1;98(2):375-383.</FONT> doi: 10.1016/j.ijrobp.2017.02.087.
Epub 2017 Feb 24. PMID: 28463157. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Arial; " ALIGN="justify"><I>Rao SR et al. Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is
associated with improved survival in patients with soft-tissue sarcoma. Cancer Med. 2022 <FONT STYLE="white-space:nowrap">Jan;11(1):194-206.</FONT> doi: 10.1002/cam4.4428. Epub 2021 Nov 27. PMID: 34837341; PMCID: PMC8704179.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Arial; " ALIGN="justify"><I>American Cancer Society statistics:
<FONT STYLE="white-space:nowrap">https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/key-statistics.html</FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><I>KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Eleanor Pearson, Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">+61 2 9066 4071;
<U>eleanor.pearson@sodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">Chris Basta,
VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">This announcement was authorised for release by the CEO of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g895636g78t64.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g895636g10b28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g895636g10b28.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !B T8# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]/: "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'GOQC^.GA?X&Z;I]
MYXDDNC]OE:*W@LX1)(^T LV"0 !E<\]QC-:TZ4JKM$Y:^)IX9)SZG8^&_$-A
MXLT#3M:TN;[3IU_ ES;RX(W(P!!P>0<'H>E9M.+LS>$U.*E'9FC2+"@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FGQP\%_#SQ
MOI>F6GQ B1X8I6DLW\R2-U; #@-'S@C&0>.G<"MJ4IQ?N'G8QX9**Q+MV_I'
M8:'+H/A_P?8'37M['P[:6J);-G;%'"  O+=L8Z\UF^9RUW.F-2E&DIQ=H6_
MP[KXU^#+5RK:TKL/^>4$CC\PN*OV4^QQ2S3!QTY_P?\ D:FD_$?PSK=I/<VF
MLVQB@7=*96\HH/4A\''O4N$EHT;T\=AJL7*,U9?+\S+;XU^#%N?).M*6SC<(
M)2O_ 'UMQ^-5[*?8P_M7!WY>?\'_ )'86-_;:G:175I/'<VTHW)+$P96'L16
M;5MSTH3C4BI0=TSGM9^)_A;0+F2WO=9@CGC8J\48:1E(Z@A0<&K4)/5(XJN/
MPU%N,YJZ^?Y%73/C#X0U>Z2V@UF-97.%$\;Q G_>90/UING-="*>9X2I+EC/
M7SNOS)];^*GA7P]<M;WFL0B=3AHX5:4J?0[ <'V-)4Y2V157,,+1?+.>OW_D
M:'AOQKHGBY'.DZC%=E!EXQE74>I5@#CWQ4RBX[HWH8JCB?X4KE'Q[\4/"WPP
MM;2Y\4:Q#H\%TYCA>978.P&2!M![4XPE/X4:5:U.BDZCL:_ASQ'IOB[0[/6-
M(NTOM-O$\R"X0$*ZYQD9 /:I:<79EPG&I%2B]&<M#\<_ EQXV/A"/Q';OXD%
MPUJ=/"2;_-7.5SMQD8/>M/93Y>:VAC]9I.?L^;4^1O\ @HY>W$?C+PI;+<2K
M;OITC-"'(1CYIY(Z$UWX1>ZSP\V;YXKR/?O!7[4_PJTWP;H-G<^,K.&YM["W
MBEC,4N5=8U!'W.Q!KDE0J.3=CTZ>-PZA%.?0]RMKF.\MHIX7$D,J!T<?Q*1D
M'\JYCT4[JZ/*_&?[5/PN\!ZK)INJ>*H&OXF*2PV4,ESY9'4,T:LH([@G/M6\
M:%22ND<=3&T*;Y92U.J^'OQ;\(?%6TEN/"NNVVK+#CS8DW)+%GH6C<!@#SR1
M@XJ)TY0^)&U*O3K*]-W'>.OBSX/^&:PGQ/X@LM'>92\44[YDD4<$JB@L1[@4
M1A*?PH*E>G1_B2L>>Q_MI?!V2Y$(\78R<;VTZZ"?F8OUK7ZO5['+_:&&O;F_
M!_Y'I]AJGASXG>&'EL+VSU[1;Q2ADMI1(A]L@\,./0@^E8M2@]=&=35+$TW%
M^]%GF7B;]G_4=2^RP6?B 2:?:@I;P7L?S0J3D@,OWOR'2MXUDMT?.5\FJ3M&
M%3W5LGT.@^'GP/T_P;>IJ-Y<?VGJ,?,1V;8XCZ@<Y/N?RJ)U7+1';@LIIX67
MM)OFE^"/3*P/="@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M$'HFON9@_P#!2'_D3_!G_7_/_P"BQ3PF[/HLV^"'J>W?LK_\F]^!_P#KP_\
M9VKFK_Q&>C@O]WAZ'QWH/_)_\O\ V,MS_)Z[Y?[O\CP8_P"__-F__P %'_\
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MJ)5J7,>9AY2P>*]DWI>W^3/T@KR#ZP* "@ H * "@ H * "@ H * "@ H *
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M^NV:1S1<J\5LL:R2 ]UVPNP/IBO5BO9T/>['S$VL1C;P[K\/^&/TKKQSZT*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M1F(WK1>7' AZK$F21GNQ.2!Q@$@\E6NZNFR/4PN"CAO>;O(]VKF/2"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * -:@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
="@ H * "@ H * "@ H * "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g895636g78t64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g895636g78t64.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !& T8# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * &3SQVT+RS2+%$BEG=V 50
M.I)/04";45=GDGB;]I7P]H]P\&FVT^LNAP94(BB/T8@D_ECWKHC1D]SY^OG5
M"F^6FN;\$9.F_M4:?-.%O] N+6(GE[>X68C\"J_SJG0?1G/#/H-^_3:7D[_Y
M'KOAGQ9I7C#3A>Z3>)=P=&"\,A]&4\@_6N>47%V9]#0Q%+$QYZ3NC7J3H"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MJ4=F3TB@H * *GV__8_6@ ^W_P"Q^M !]O\ ]C]: #[?_L?K0 ?;_P#8_6@
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M*\ZI\;/T?+&W@Z?-_6IVOV__ &/UK,],/M_^Q^M !]O_ -C]: *E !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'SC^T%X(FTS7SK]O&6L;[ F
M91Q'*!CGV8 'ZYKMHSNN4^(SG".G5]O':6_K_P $S] &H_#+P<OBK3-4B%YJ
M86V6$*&6-<DDX.=S J.W&3UJG:<N5HYJ/M,#0^LTY:RT_KS.9\3?$OQ+XO>(
MZGJDLBQ'=''$!$BGUPH&3[GFKC",=D<5?&XC$6]I+;Y?D36RZS\6O%EG P1[
MIT6)I8X]JQQKU=L>F3^@'84G:G$N*K9C7C'K^G<^M=,T^'2=.M;*W7;!;1+%
M&/15&!_*O/;N[GZ/3@J<%".RT+-(L* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H @OK&WU.SEM;N%+BVE7:\4BY5A[BFG;5$3A&I%QFK
MIGC?B?\ 9MMKF5YM"U$V@)R+6[!=!]''('U!^M=,:]OB1\SB,CC)WH2MY/\
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M4E6<.;12A*7W-KMHE;5:MZ6ZI3B\3*AS*"NU.$?_  )7WOJWTT26M^[ZB?\
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M%7E",I5.BNU9IJS5VFW:2BG=M=%I<=XN^.,$?A[51X>TO5M0U1;6_EMWMXH
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M7JO/0]/KE.X* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZW+A3C!P:O>+NM7?5IO6][.RNKVT2L;,7A'28O"L/AP6BC1HK9;1;925 C4
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M5&XKG P:B$Y4U:/G\N9-.W:]WMWON54HPJOFFM=.K5^5IJ]M[-*U^UMBM/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
$@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
